Trials / Completed
CompletedNCT03786770
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Revance Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2a, multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines (FHL) (frontalis) in conjunction with treatment of the glabellar complex.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DaxibotulinumtoxinA for injection | Intramuscular injection |
Timeline
- Start date
- 2019-01-24
- Primary completion
- 2020-03-09
- Completion
- 2020-03-09
- First posted
- 2018-12-26
- Last updated
- 2023-02-16
- Results posted
- 2023-02-16
Locations
4 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03786770. Inclusion in this directory is not an endorsement.